NUVO PHARMACEUTICALS (IRELAND) DAC – Trademark Portfolio

Entity Type: 99

NUVO PHARMACEUTICALS (IRELAND) DAC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include NUVIGIL and PROVIGIL. The owner is based in DUBLIN.

88 HARCOURT STREET,

DUBLIN D02 DK18 , IE

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NUVIGIL
NUVIGIL
Registered 2004
PROVIGIL
PROVIGIL
Cancelled 2000
PROVIGIL
PROVIGIL
Registered 1994

Trademark Classifications

NUVO PHARMACEUTICALS (IRELAND) DAC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does NUVO PHARMACEUTICALS (IRELAND) DAC have?

NUVO PHARMACEUTICALS (IRELAND) DAC has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 cancelled.

What trademark classes does NUVO PHARMACEUTICALS (IRELAND) DAC file in?

NUVO PHARMACEUTICALS (IRELAND) DAC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NUVO PHARMACEUTICALS (IRELAND) DAC's most well-known trademarks?

NUVO PHARMACEUTICALS (IRELAND) DAC's registered trademark portfolio includes well-known marks such as NUVIGIL and PROVIGIL. These are among 2 currently registered trademarks in the portfolio.

What is NUVO PHARMACEUTICALS (IRELAND) DAC's trademark registration success rate?

NUVO PHARMACEUTICALS (IRELAND) DAC has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.